These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10955863)

  • 1. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
    Miller DS; Blessing JA; Kilgore LC; Mannel R; Van Le L
    Am J Clin Oncol; 2000 Aug; 23(4):355-7. PubMed ID: 10955863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
    Miller DS; Blessing JA; Schilder J; Munkarah A; Lee YC
    Gynecol Oncol; 2005 Aug; 98(2):217-21. PubMed ID: 15975641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
    Miller DS; Blessing JA; Lentz SS; Waggoner SE
    Gynecol Oncol; 2002 Dec; 87(3):247-51. PubMed ID: 12468321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
    Kunos C; Deng W; Dawson D; Lea JS; Zanotti KM; Gray HJ; Bender DP; Guaglianone PP; Carter JS; Moore KN
    Int J Gynecol Cancer; 2015 Mar; 25(3):484-92. PubMed ID: 25594147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241).
    Macdonald JS; Benedetti JK; Modiano M; Alberts DS
    Invest New Drugs; 1997; 15(4):357-9. PubMed ID: 9547679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
    Fiorica JV; Blessing JA; Puneky LV; Secord AA; Hoffman JS; Yamada SD; Buekers TE; Bell J; Schilder JM;
    Gynecol Oncol; 2009 Nov; 115(2):285-9. PubMed ID: 19726073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of topotecan in the treatment of serous carcinoma of the uterus.
    Chambers JT; Rutherford TJ; Schwartz PE; Carcangiu ML; Chambers SK; Baker L
    Int J Gynecol Cancer; 2003; 13(2):216-22. PubMed ID: 12657127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS; Blessing JA; Lentz SS; McMeekin DS
    Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Muderspach LI; Blessing JA; Levenback C; Moore JL
    Gynecol Oncol; 2001 May; 81(2):213-5. PubMed ID: 11354055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
    Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.
    Shimada M; Sato S; Oishi T; Itamochi H; Kigawa J; Takeshima N; Aoki D; Aoki Y; Nambu Y; Ochiai K
    Int J Clin Oncol; 2016 Oct; 21(5):969-974. PubMed ID: 27142771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.
    Brown JV; Peters WA; Rettenmaier MA; Graham CL; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2003 Feb; 88(2):136-40. PubMed ID: 12586592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
    Lorusso D; Mainenti S; Pietragalla A; Fusco E; Malaguti P; Masciullo V; Scambia G
    Oncology; 2011; 80(5-6):390-4. PubMed ID: 21829040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
    Piura B; Rabinovich A
    Int J Gynecol Cancer; 2005; 15(4):612-7. PubMed ID: 16014114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.